Angel’s pipeline will feature Corvus’ three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and its preclinical BTK inhibitor programStrategic […]
RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2020 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company […]
BridgeBio to Acquire All Outstanding Shares of Eidos it Does Not Already OwnAgreement Brings BridgeBio’s Clinical Development and Commercial Development […]